Cardax

Cardax Equity Growth

The Year-over-Year Equity Growth of Cardax (CDXI) as of Oct 19, 2026 is -41.66 %. In the previous year, Year-over-Year Equity Growth was -103.62 % — a change of -59.80% (higher).

Equity Growth

-41.66 %

YoY

-59.80%

Last updated:

Year-over-Year Equity Growth of Cardax is 2020 -41.66 % . Year-over-Year Equity Growth of Cardax was 2019 -103.62 % . It decreases by -59.80% higher compared to the previous year.

The Cardax Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2016
-3.67 USD
Jan 1, 2017
63.83 USD
Jan 1, 2018
-151.54 USD
Jan 1, 2019
-103.62 USD
Jan 1, 2020
-41.66 USD
The Cardax Equity Growth history
YEAREquity GrowthYoY
-41.66 %-59.80%
-103.62 %-31.62%
-151.54 %-337.42%
63.83 %-1,838.50%
-3.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

Year-over-Year Equity Growth of Cardax is -41.66 % in 2020.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Cardax since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Cardax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cardax

All Key Metrics — Cardax